Alcohol-related posterior reversible encephalopathy syndrome: a case report of a patient managed with a benzodiazepine-sparing regimen for alcohol withdrawal
We report a case of posterior reversible encephalopathy syndrome (PRES) during treatment for alcohol withdrawal syndrome with gabapentin and clonidine. The patient developed severe hypertension, confusion and tremor, culminating in bilateral vision loss and a seizure. Imaging revealed posterior cerebral edema. Treatment with benzodiazepines, antihypertensives, and anti-seizure medications led to resolution. One year later, imaging showed resolution of the findings. We review the associated literature and propose the recognition of a PRES sub-entity, Alcohol-Related PRES (ARPRES), which can appear in the setting of alcohol ...
Source: Neurocase - May 3, 2024 Category: Neurology Authors: Rafail A Chionatos David P Lerner Joseph D Burns Anil Ramineni Source Type: research
An acute phase reaction from zoledronate mimicking symptoms seen in opioid withdrawal: a case report
CONCLUSION: Zoledronate, well known for causing acute phase reactions, was likely the cause of withdrawal-like symptoms. Acute phase reactions with bisphosphonates mostly occur in the first infusion, and the incidence decreases with subsequent infusions. Symptoms typically occur 24-72 h post-infusion, and last at most for 72 h. Cognitive bias led the primary team to be concerned with opioid withdrawal rather than investigating other causes for the patient's presentation. Therefore, providers should thoroughly investigate potential etiologies and rule them out accordingly to provide the best care. Health care providers shou...
Source: Addiction Science and Clinical Practice - May 1, 2024 Category: Addiction Authors: Pankti P Acharya Crystal Joseph Source Type: research
An acute phase reaction from zoledronate mimicking symptoms seen in opioid withdrawal: a case report
CONCLUSION: Zoledronate, well known for causing acute phase reactions, was likely the cause of withdrawal-like symptoms. Acute phase reactions with bisphosphonates mostly occur in the first infusion, and the incidence decreases with subsequent infusions. Symptoms typically occur 24-72 h post-infusion, and last at most for 72 h. Cognitive bias led the primary team to be concerned with opioid withdrawal rather than investigating other causes for the patient's presentation. Therefore, providers should thoroughly investigate potential etiologies and rule them out accordingly to provide the best care. Health care providers shou...
Source: Addiction Science and Clinical Practice - May 1, 2024 Category: Addiction Authors: Pankti P Acharya Crystal Joseph Source Type: research
Advancing Postoperative Pain Management in Oral Cancer Patients: A Systematic Review
Pharmaceuticals (Basel). 2024 Apr 22;17(4):542. doi: 10.3390/ph17040542.ABSTRACTThe goal of this review is to shed light on the management of orofacial discomfort after a cancer diagnosis in the head and neck region. A search was conducted on PubMed, Scopus, and Web of Science to identify studies on postoperative pain control in oral cancer. The review included open-access research, investigations into pain management, randomized clinical trials, retrospective studies, case-control studies, prospective studies, English-written studies, and full-text publications. Exclusion criteria included animal studies; in vitro studies...
Source: Cancer Control - April 27, 2024 Category: Cancer & Oncology Authors: Angelo Michele Inchingolo Gianna Dipalma Alessio Danilo Inchingolo Irene Palumbo Mariafrancesca Guglielmo Roberta Morolla Antonio Mancini Francesco Inchingolo Source Type: research
Efficacy and Safety of Gabapentinoids for Acute Herpes Zoster Neuralgia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
CONCLUSION: Gabapentin can effectively reduce acute herpes zoster neuralgia in patients. Pregabalin requires additional randomized controlled trials to supplement the analysis.PROSPERO REGISTRATION: CRD42023446643.PMID:38651606 | DOI:10.1097/AJP.0000000000001218 (Source: Herpes)
Source: Herpes - April 23, 2024 Category: Infectious Diseases Authors: Yinluo Li Xingzhen Long Fengrong Luo Jiarui Zhang Shaoqin Sun Pengqiang Du Hongtao Yang Qi Chen Changcheng Sheng Xue Bai Source Type: research
Efficacy and Safety of Gabapentinoids for Acute Herpes Zoster Neuralgia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
CONCLUSION: Gabapentin can effectively reduce acute herpes zoster neuralgia in patients. Pregabalin requires additional randomized controlled trials to supplement the analysis.PROSPERO REGISTRATION: CRD42023446643.PMID:38651606 | DOI:10.1097/AJP.0000000000001218 (Source: Herpes)
Source: Herpes - April 23, 2024 Category: Infectious Diseases Authors: Yinluo Li Xingzhen Long Fengrong Luo Jiarui Zhang Shaoqin Sun Pengqiang Du Hongtao Yang Qi Chen Changcheng Sheng Xue Bai Source Type: research
Neuropathic pain: Evidence based recommendations
Presse Med. 2024 Apr 17:104232. doi: 10.1016/j.lpm.2024.104232. Online ahead of print.ABSTRACTNeuropathic pain continues to be a significant problem that lacks effective solutions for every single patient. In 2015, international guidelines (NeuPSIG) were published, while the French recommendations were updated in 2020. The purpose of this minireview is to provide an update on the process of developing evidence-based recommendations and explore potential changes to the current recommendations. Primary treatments for neuropathic pain include selective serotonin-norepinephrine reuptake inhibitors (SNRIs) such as duloxetine an...
Source: Presse Medicale - April 19, 2024 Category: General Medicine Authors: Xavier Moisset Source Type: research
Neuropathic pain: Evidence based recommendations
Presse Med. 2024 Apr 17:104232. doi: 10.1016/j.lpm.2024.104232. Online ahead of print.ABSTRACTNeuropathic pain continues to be a significant problem that lacks effective solutions for every single patient. In 2015, international guidelines (NeuPSIG) were published, while the French recommendations were updated in 2020. The purpose of this minireview is to provide an update on the process of developing evidence-based recommendations and explore potential changes to the current recommendations. Primary treatments for neuropathic pain include selective serotonin-norepinephrine reuptake inhibitors (SNRIs) such as duloxetine an...
Source: Presse Medicale - April 19, 2024 Category: General Medicine Authors: Xavier Moisset Source Type: research
Neuropathic pain: Evidence based recommendations
Presse Med. 2024 Apr 17:104232. doi: 10.1016/j.lpm.2024.104232. Online ahead of print.ABSTRACTNeuropathic pain continues to be a significant problem that lacks effective solutions for every single patient. In 2015, international guidelines (NeuPSIG) were published, while the French recommendations were updated in 2020. The purpose of this minireview is to provide an update on the process of developing evidence-based recommendations and explore potential changes to the current recommendations. Primary treatments for neuropathic pain include selective serotonin-norepinephrine reuptake inhibitors (SNRIs) such as duloxetine an...
Source: Presse Medicale - April 19, 2024 Category: General Medicine Authors: Xavier Moisset Source Type: research
Unintended Consequences of Opioid Policy on Disparities in Pain Management for Older Adults with Serious Illness
1. Characterize opioid and anticonvulsant (gabapentin, pregabalin) prescribing trends from 2010-2020 among older adults with dementia (PWD) and older adults with cancer (PWC).2. Identify the association of the 2016 CDC opioid guideline with racial/ethnic disparities in opioid prescribing among PWD and PWC. (Source: Journal of Pain and Symptom Management)
Source: Journal of Pain and Symptom Management - April 19, 2024 Category: Palliative Care Authors: Rebecca Rodin, Lihua Li, Duzhi Zhao, Karen McKendrick, Melissa Aldridge, R. Sean Morrison Source Type: research
Pharmacotherapy and noninvasive neurostimulation for neuropathic pain
Presse Med. 2024 Apr 16:104233. doi: 10.1016/j.lpm.2024.104233. Online ahead of print.ABSTRACTNeuropathic pain poses a significant challenge due to its complex mechanisms, necessitating specific treatments. In recent decades, significant progress has been made in the clinical research of neuropathic pain, marking a shift from empirical strategies to evidence-based medicine in its management. This review outlines both pharmacological and non-pharmacological interventions. Antidepressants (tricyclic and serotonin-noradrenaline reuptake inhibitors), antiepileptics (gabapentin, pregabalin), and topical agents constitute the ma...
Source: Presse Medicale - April 18, 2024 Category: General Medicine Authors: Annachiara Spagna Nadine Attal Source Type: research
Spinal neuronal activity and neuroinflammatory component in a mouse model of CFA-induced vestibulodynia
In conclusion, our study provides a comprehensive understanding of the CFA-induced model of vestibulodynia, encompassing behavioral, neurophysiological and neuroinflammatory aspects. These data pave the way to investigate spinal cord first pain plasticity in vestibulodynia.PMID:38636564 | DOI:10.1016/j.bbi.2024.04.012 (Source: Brain, Behavior, and Immunity)
Source: Brain, Behavior, and Immunity - April 18, 2024 Category: Neurology Authors: Serena Boccella Michela Perrone Antimo Fusco Roozbe Bonsale Rosmara Infantino Silvia Nuzzo Giovanni Pecoraro Federica Ricciardi Andrea Maria Morace Gianluca Petrillo Ilaria Leone Monica Franzese Vito de Novellis Francesca Guida Marco Salvatore Sabatino Ma Source Type: research
Calcineurin regulates synaptic Ca < sup > 2+ < /sup > -permeable AMPA receptors in hypothalamic presympathetic neurons via α2δ-1-mediated GluA1/GluA2 assembly
J Physiol. 2024 Apr 17. doi: 10.1113/JP286081. Online ahead of print.ABSTRACTHypertension is a major adverse effect of calcineurin inhibitors, such as tacrolimus (FK506) and cyclosporine, used clinically as immunosuppressants. Calcineurin inhibitor-induced hypertension (CIH) is linked to augmented sympathetic output from the hypothalamic paraventricular nucleus (PVN). GluA2-lacking, Ca2+-permeable AMPA receptors (CP-AMPARs) are a key feature of glutamatergic synaptic plasticity, yet their role in CIH remains elusive. Here, we found that systemic administration of FK506 in rats significantly increased serine phosphorylation...
Source: The Journal of Physiology - April 17, 2024 Category: Physiology Authors: Jing-Jing Zhou Jian-Ying Shao Shao-Rui Chen Hong Chen Hui-Lin Pan Source Type: research
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder
Expert Opin Emerg Drugs. 2024 Apr 12. doi: 10.1080/14728214.2024.2342951. Online ahead of print.ABSTRACTINTRODUCTION: Alcohol Use Disorder (AUD) poses an ongoing significant global health burden. AUD is highly prevalent and affects not only the individuals with AUD, but also their communities and society at large. Even though pharmacotherapy is an integral part of AUD treatment, the few available substances show limited efficacy and limited clinical impact. Thus, there is a need for new innovative pharmacotherapeutic approaches.AREAS COVERED: This paper provides a comprehensive review of drugs approved for the treatment of...
Source: Expert Opinion on Emerging Drugs - April 12, 2024 Category: Drugs & Pharmacology Authors: Sophie K öhne Thomas Hillemacher Alexander Glahn Patrick Bach Source Type: research
